Fractyl Health, INC

Fractyl Health announced one-year results from its REMAIN-1 Midpoint Cohort, showing its Revita DMR System maintained significant weight loss after GLP-1 discontinuation.

Fractyl Health, Inc. successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of three Class II directors and the ratification of its independent auditors.

Fractyl Health announces positive one-year results from its REVEAL-1 study, showing sustained weight maintenance after a single Revita procedure post-GLP-1 therapy.

Fractyl Health announced first quarter 2026 financial results, reiterating key clinical and regulatory milestones for its Revita and Rejuva platforms, and maintaining cash runway guidance into early 2027.

Fractyl Health announced authorization in the Netherlands to begin a Phase 1/2 human study for RJVA-001, a novel gene therapy targeting type 2 diabetes, marking a significant step towards a dual clinical-stage company.

Fractyl Health announced Q4 and full-year 2025 financial results, highlighted positive Revita clinical data, and reiterated its cash runway into early 2027.

Fractyl Health reports a significant swing to net income in Q1 2026, driven by favorable changes in warrant liabilities, despite a decrease in research and development expenses.

Fractyl Health, Inc. reported a significant increase in net loss for Q3 2025, alongside positive 3-month data from its Revita REMAIN-1 Midpoint Cohort and progress in its Rejuva gene therapy platform.

Fractyl Health, Inc. reported significant net losses and a going concern warning, despite progress in clinical trials and a recent capital raise deemed insufficient for long-term operations.

Fractyl Health is focusing on its REMAIN-1 pivotal study and advancing its Rejuva gene therapy platform after a strategic reprioritization.

Fractyl Health's Q3 2024 report details financial results and progress in clinical trials for their metabolic disease therapies.

Fractyl Health's second quarter 2024 results show increased operating expenses due to clinical trial advancements and public company costs, alongside a net loss of $20.6 million.

Fractyl Health, a clinical-stage metabolic therapeutics company, reported significant net losses and raised substantial doubt about its ability to continue as a going concern, despite advancing its Revita and Rejuva product candidates.

Fractyl Health refocuses on its weight loss maintenance program after positive preliminary results, pausing investment in its type 2 diabetes initiatives.

Fractyl Health's 10-K filing details its capital structure, registration rights, and strategic focus on developing therapies for metabolic diseases.

Director Ajay Royan purchased 23,000 shares of Fractyl Health, Inc. (GUTS) at an average price of $0.852 per share.

Director William Bradley acquired 68,493 shares of Fractyl Health (GUTS) and received a stock option grant for 22,500 shares.

Director Samuel Conaway was granted 22,500 stock options as part of Fractyl Health's non-employee director compensation policy.

Director Ajay Royan was granted 22,500 stock options as part of Fractyl Health's non-employee director compensation policy.

Director Christopher Charles Thompson was granted 22,500 stock options as part of Fractyl Health's non-employee director compensation policy.

Director Marc Elia was granted 22,500 stock options as part of Fractyl Health's non-employee director compensation policy.

Fractyl Health announces its 2026 Annual Meeting of Stockholders to be held virtually on June 10, 2026.

Fractyl Health, Inc. will hold a special meeting on October 3, 2025, to seek stockholder approval for the issuance of common stock upon the exercise of Tranche B Warrants, crucial for funding its pipeline programs and extending its cash runway.

Fractyl Health, Inc. has filed a definitive proxy statement with the SEC, soliciting material under Section 240.14a-12.

Fractyl Health announces its 2025 Annual Meeting of Stockholders to be held virtually on June 11, 2025, featuring proposals for director elections and ratification of the company's independent auditor.

Fractyl Health, a metabolic therapeutics company, is seeking to raise $110 million through an initial public offering to fund the development of its Revita and Rejuva therapies targeting type 2 diabetes and obesity.

683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman have reported beneficial ownership of 7,679,615 shares of Fractyl Health, Inc. common stock, representing 4.81% of the outstanding shares.

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 3,606,386 shares, representing 2.3% of Fractyl Health Inc.'s Class A Common Stock as of March 31, 2026.

Mithril LP and affiliated entities, including Ajay Royan and Peter Thiel, reported a decrease in their aggregate beneficial ownership of Fractyl Health, Inc. common stock to 4.7% due to the issuer's recent share sales.

CVF, LLC and HCC Manager LLC have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 3.4% of Fractyl Health, Inc.'s common stock.

Alyeska Investment Group, L.P. and its affiliates have disclosed a 9.7% beneficial ownership stake in Fractyl Health's Class A Common Stock.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in Fractyl Health, Inc. as of September 30, 2025.